"While GLP-1 medications affect gastrointestinal tract motility, their quantified impact may not be as significant as previously assumed, said corresponding author, Dr Walter Chan, director of the Center of Gastrointestinal Motility and a physician in the Brigham's Division of Gastroenterology, Hepatology and Endoscopy
Begin with the retatrutide protocol alone, establish tolerability, confirm that the primary compound is producing the expected effects, and only then consider carefully selected adjuncts based on specific, measurable goals
Vendors advertising it online are offering an unapproved research chemical of unverified purity
Launch follows 13 months later
Using the latest advancements in injectable weight loss therapies (GLP-1s) and expert nutritional counseling, his approach focuses on metabolic optimization, sustainable habits, and long-term results